Clinical pharmacology of antifungal agents in pediatric patients

Christine C. Chiou, Thomas J. Walsh, Andreas H. Groll

Research output: Contribution to journalReview articlepeer-review


Invasive fungal infections have emerged as important causes of morbidity and mortality in profoundly immunocompromised children including cancer, transplant and intensive care unit patients. Present treatment strategies for these infections are limited by toxicity, drug interactions and expense. In order to overcome these limitations, new antifungal compounds are being developed, which may improve the therapeutic armamentarium for prevention and treatment of invasive mycoses in high-risk children. This article summarizes the clinical pharmacology of established and newly developed antifungal agents, including new triazoles and echinocandins in pediatric age groups.

Original languageEnglish (US)
Pages (from-to)2465-2489
Number of pages25
JournalExpert opinion on pharmacotherapy
Issue number15
StatePublished - Oct 2007
Externally publishedYes


  • Amphotericin
  • Anidulafungin
  • Antifungal agent
  • Caspofungin
  • Children
  • Fluconazaole
  • Flucytosine
  • Itraconazole
  • Micafungin
  • Mycoses
  • Pharmacology
  • Posaconazole
  • Voriconazole

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Clinical pharmacology of antifungal agents in pediatric patients'. Together they form a unique fingerprint.

Cite this